On January 2nd, Xinda Biotechnology and Roche reached a global cooperation agreement to grant Roche the development, production, and commercialization rights of the new generation ADC drug IBI3009 targeting DLL3. The total transaction amount is up to $1.08 billion, including a down payment of $80 million and milestone payments. The drug has been administered to the first patient in phase I clinical trials for small cell lung cancer (SCLC) and is planned to be developed in combination with Roche PD-L1 inhibitor atezolizumab.

On January 7th, Yingen Biotechnology awarded Avenzo Therapeutics the overseas rights to the EGFR/HER3 dual antibody ADC drug DB-1418, receiving a down payment of $50 million and a milestone payment of up to $1.15 billion; On January 13th, its HER2 ADC drug DB-1303 received a down payment of $25 million and a milestone payment of $42 million from Sansheng Pharmaceutical, accelerating its commercial layout in China. According to incomplete statistics, Yingen Biotechnology has accumulated a potential amount of over 5 billion US dollars through 6 ADC authorization transactions since 2023, leading the domestic ADC market.

On January 24th, Qide Pharmaceutical held a major business cooperation signing ceremony at its research and development headquarters in Suzhou, reaching significant business cooperation agreements with American pharmaceutical company Biohaven and South Korean pharmaceutical company AimedBio. The cooperation includes exclusive authorization for the global development and commercialization of the first ADC drug GQ1011 by Qide Pharmaceutical, as well as authorization for innovative bio coupling core platform technology, empowering ADC drug innovation for a total of 21 targets with partners in the United States and South Korea, with a total transaction amount exceeding 13 billion US dollars.

On January 22nd, Lepu Biotechnology (02157. HK) partnered with ArriVent Biopharma, a Nasdaq listed company, Inc. (AVBP. O, hereinafter referred to as ArriVent) has reached a global exclusive licensing agreement worth over $1.2 billion for MRG007, a potential best in class antibody conjugate drug for gastrointestinal cancer. Lepu Biotech has secured a one-time payment of up to $47 million for initial and recent milestones, and is expected to achieve milestone revenues of up to $1.16 billion in key stages such as development, registration, and sales in the future. In addition, the company will also receive tiered royalty fees based on net sales in markets outside of Greater China.

On February 19th, Shiyao Group announced that it has reached an agreement with Radiance Biopharma, which will obtain the development and commercialization rights of the recombinant anti human receptor tyrosine kinase like orphan receptor 1 (ROR1) antibody coupled drug SYS6005 project independently developed by Shiyao Group within a certain regional scope. Giant Stone Biology will receive a down payment of $15 million; And corresponding milestone payments, with a cumulative development milestone payment not exceeding $150 million and a cumulative sales milestone payment not exceeding $1.075 billion. The total amount shall not exceed 1.24 billion US dollars.

Source: https://pharm.jgvogel.cn/c1501236.shtml